475 related articles for article (PubMed ID: 17785355)
1. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.
Lupi C; Giannini R; Ugolini C; Proietti A; Berti P; Minuto M; Materazzi G; Elisei R; Santoro M; Miccoli P; Basolo F
J Clin Endocrinol Metab; 2007 Nov; 92(11):4085-90. PubMed ID: 17785355
[TBL] [Abstract][Full Text] [Related]
2. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
[TBL] [Abstract][Full Text] [Related]
3. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
4. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.
Basolo F; Torregrossa L; Giannini R; Miccoli M; Lupi C; Sensi E; Berti P; Elisei R; Vitti P; Baggiani A; Miccoli P
J Clin Endocrinol Metab; 2010 Sep; 95(9):4197-205. PubMed ID: 20631031
[TBL] [Abstract][Full Text] [Related]
5. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
Jo YS; Li S; Song JH; Kwon KH; Lee JC; Rha SY; Lee HJ; Sul JY; Kweon GR; Ro HK; Kim JM; Shong M
J Clin Endocrinol Metab; 2006 Sep; 91(9):3667-70. PubMed ID: 16772349
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
7. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R
Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287
[TBL] [Abstract][Full Text] [Related]
8. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma.
Trovisco V; Soares P; Soares R; Magalhães J; Sá-Couto P; Sobrinho-Simões M
Hum Pathol; 2005 Jun; 36(6):694-7. PubMed ID: 16021577
[TBL] [Abstract][Full Text] [Related]
9. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR.
Jeong D; Jeong Y; Park JH; Han SW; Kim SY; Kim YJ; Kim SJ; Hwangbo Y; Park S; Cho HD; Oh MH; Yang SH; Kim CJ
Ann Surg Oncol; 2013 Mar; 20(3):759-66. PubMed ID: 23179992
[TBL] [Abstract][Full Text] [Related]
10. Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.
Kim MH; Bae JS; Lim DJ; Lee H; Jeon SR; Park GS; Jung CK
Endocr Relat Cancer; 2014; 21(6):891-902. PubMed ID: 25266729
[TBL] [Abstract][Full Text] [Related]
11. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
[TBL] [Abstract][Full Text] [Related]
12. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
13. Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers.
Li C; Aragon Han P; Lee KC; Lee LC; Fox AC; Beninato T; Thiess M; Dy BM; Sebo TJ; Thompson GB; Grant CS; Giordano TJ; Gauger PG; Doherty GM; Fahey TJ; Bishop J; Eshleman JR; Umbricht CB; Schneider EB; Zeiger MA
J Clin Endocrinol Metab; 2013 Sep; 98(9):3702-12. PubMed ID: 23969188
[TBL] [Abstract][Full Text] [Related]
14. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
[TBL] [Abstract][Full Text] [Related]
15. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
16. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
[TBL] [Abstract][Full Text] [Related]
17. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
[TBL] [Abstract][Full Text] [Related]
18. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.
Wang Y; Ji M; Wang W; Miao Z; Hou P; Chen X; Xu F; Zhu G; Sun X; Li Y; Condouris S; Liu D; Yan S; Pan J; Xing M
Endocr Relat Cancer; 2008 Mar; 15(1):183-90. PubMed ID: 18310286
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
20. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma.
Giannini R; Ugolini C; Lupi C; Proietti A; Elisei R; Salvatore G; Berti P; Materazzi G; Miccoli P; Santoro M; Basolo F
J Clin Endocrinol Metab; 2007 Sep; 92(9):3511-6. PubMed ID: 17535994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
